Introduction
Antimicrobial peptides (AMPs) are small proteins (<40 amino acids) with a potential to eliminate a wide range of pathogenic microorganisms. They are encoded in the genomes of both vertebrates and invertebrates (Zasloff 2002; Noga et al. 2011) and act as important components of the innate immune system primarily by killing pathogens through disruption of the bacterial membrane although they also may display immunomodulatory activities (Ganz 2003; Hancock & Sahl 2006) . A large number of these peptides have been identified in several fish species (Uzzell et al. 2003; Chang et al. 2005; Chang et al. 2006; Maier et al. 2008; Smith & Fernandes 2009; Rajanbabu & Chen 2011; Masso-Silva & Diamond 2014) suggesting an evolutionary old role in immunity. Following extensive usage of antibiotics in human and veterinary medicine for decades emergence of antibiotic resistance in a series of bacterial pathogens, some which may infect fish, has been recorded (Cabello 2006 ). This has raised growing concern for future control of fish diseases and new and alternative antimicrobial peptides with a therapeutic potential have therefore been in focus (Jia et al. 2000; Douglas 2011) . It is noteworthy that development of bacterial resistance to these peptides is less readily developed compared to conventional antibiotics (Steinberg et al. 1997; Cabello 2006; Noga et al. 2011) . A range of synthetic antimicrobial peptides have been developed and clinically tested but only a limited number of them have confirmed the expected efficacy (Hancock & Sahl 2006; Zhang & Falla 2006) . In addition, a limitation associated with the use of these peptides as antibiotics is the potential cytotoxicity associated with systemic application. Finally some of the peptides are not resistant to proteases potentially losing their function following oral administration (Travis et al. 2000; Hancock & Sahl 2006) . AMP application for control and treatment of yersiniosis in rainbow trout Oncorhynchus mykiss (Walbaum) has not been investigated previously. Therefore, the present study was undertaken to elucidate if a synthetic AMP, belonging to the cathelicidin family, has an antibiotic effect against Yersinia ruckeri infection in rainbow trout. We investigated three synthetic broad-spectrum antimicrobial peptides (CAP11, CAP11-1-18 m2 and CAP18) which recently have shown in vitro effect against Y. ruckeri (Ebbensgaard et al. 2015) . Prior to the in vivo experiment, the cytotoxicity of these peptides for fish cells (rainbow trout red blood cells) was assessed in a haemolytic assay and the non-toxic AMP (CAP18) was selected for further in vivo work comparing administration methods (intraperitoneal AMP injection and oral AMP administration in feed). Different groups of rainbow trout receiving CAP18 were then exposed to Y. ruckeri infection (1-h bath challenge) and the disease progression was subsequently recorded and compared to non-medicated control fish and fish receiving a conventional antibiotic (oxolinic acid).
Materials and methods
Cathelicidin peptides CAP11 (94.7% purity), CAP11-1-18 m2 (87.9% purity) and CAP18 (89.5% purity), were designed and synthesized by GenScript (USA). These AMPs showed generally high in vitro antimicrobial activities, that is minimum inhibitory concentration (MIC) value of 2-64 mg L À1 , against Gram-negative bacteria including Y. ruckeri (Ebbensgaard et al. 2015) .
Haemolysis assay
The cytotoxicity of these AMPs was determined by measuring the released haemoglobin from rainbow trout red blood cells. Blood samples were collected by caudal vein puncture from rainbow trout juveniles (10-12 g) using heparinized syringes and transferred to Eppendorf tubes each containing 100 lL heparin. The blood sample was diluted with PBS and centrifuged at 4696 g for 5 min. The supernatant was discarded and RBC resuspended in PBS containing 100 lL heparin whereupon the cell number was adjusted to 10 6 cells mL À1 . Dilution series (1:10-1:1000) of antimicrobial peptides CAP11, CAP11-1-18m2 and CAP18 (all in basic concentrations of 10 mg mL À1 ) were prepared in a 96-well plate, and 100 lL of the RBC suspension was added to each well, which was then incubated at room temperature (18°C) in an orbital shaker (50 rpm) for 1 h. The plate was subsequently centrifuged at 4696 g for 5 min, and the supernatant (100 lL) was transferred to another plate and read at 540 nm in ELISA plate reader, Epoch Microplate Spectrophotometer (Holm & Halby), to measure released haemoglobin. Triton X-100 (0.2%) was used as positive control, as it caused 100% haemolysis, and PBS was applied as negative control. CAP18 and CAP11-1-18m2 were dissolved in water, while dimethyl sulphoxide (DMSO) was used for dissolving CAP11. Therefore, not only PBS but also DMSO was tested alone to examine the effect of this solvent on fish RBCs.
Infection experiments
Based on the results of the haemolytic assay, CAP18 was selected because it showed the lowest haemolytic effect on fish RBCs making it the best candidate for further in vivo experiments. Two experiments were performed to determine the functional effective dose of CAP18. This was followed by two main experiments where the selected dose of CAP18 was used on a larger number of fish. For these trials, administration by intraperitoneal (i.p.) injection and the oral route (in feed) were tested.
Experimental fish
For all experiments, we used rainbow trout (Fousing strain) fry (2-5 g), hatched and reared in a pathogen-free facility at the Salmon Hatchery, and acclimatized for 1-2 weeks before experimentation. Upon arrival at the university fish-keeping unit, the pathogen-free status of fish was confirmed by examining 2-3 fish for bacterial (head kidney swabs) and parasitic infection (Buchmann 2007) . During the acclimatization period, water temperature was slowly increased until the desired temperature of 15-16°C and a light-dark scheme (12/12-h light/dark) was attained. Fish were fed (1.5% of biomass per day) with commercial standard pelleted feed (Inicio 917; BioMar A/S) until challenge.
Dose adjustment experiments for i.p. injection of CAP18. In the first experiment, rainbow trout fry were anaesthetized in MS222 (50 mg L À1 ) (Sigma-Aldrich) and intraperitoneally injected with 0.1 mL of an aqueous solution containing different amounts of the antimicrobial peptide CAP18, that is 50 lg, 100 lg, 200 lg and 400 lg per fish. Control fish were only injected with sterile distilled water. Fish from all the groups were stocked together in the same aquaria, and tagging of different groups of fish was performed by partial fin clipping (upper caudal fin, lower caudal fin or adipose fin). One hour postinjection with CAP18, fish were challenged by bath exposure to Y. ruckeri O1 biotype 2 (5.6 9 10 8 CFU mL À1 ) for 1 h. Subsequently, fish were transferred to clean water and maintained until 15 days post-infection (dpi). The fish were examined every second hour, and moribund fish were removed and killed in a lethal overdose of MS222 (300 mg L À1 ) (according to the animal welfare guidelines of the University of Copenhagen, Denmark).
Efficacy testing experiment. According to the results from the preliminary experiments, the effective dose of 400 lg CAP18 per fish was selected for the main experiment. Groups of fish receiving the antibiotic oxolinic acid (at 200 mg kg À1 body weight) were included as positive controls. A total of six treatments groups with replicate tanks for each group were set up. Rainbow trout fry were anaesthetized in MS222 and intraperitoneally injected (0.1 mL) with the antimicrobial peptide CAP18 (400 lg per fish) or the antibiotic oxolinic acid (200 mg kg À1 body weight). One hour post-injection with AMP or oxolinic acid, fish were challenged by bath exposure to Y. ruckeri O1 biotype 2 (4 9 10 6 CFU mL À1 ) in 5 L water volume for 6 h, and then, the fish tank water level was raised up to 20 L diluting the bacterial concentration to 1 9 10 6 CFU mL À1 . Fish were allowed to swim in this bacterial solution for 18 h after which water was totally replaced with fresh tap water and fish were maintained until 14 dpi. The fish were examined every second hour, and moribund fish were killed and recorded. Three control groups comprising unmedicated fish, CAP18injected fish and oxolinic acid-injected fish were kept uninfected.
Oral administration (CAP18 in feed)
Based on the results of the i.p. injection experiment, the dose of 400 lg CAP18 per fish was chosen for the in-feed-based delivery of AMP. Due to the risk of proteolytic degradation of AMPs in the fish digestive tract and risk of CAP18 leaching into the water, we also tested a higher dose, 800 lg CAP18 per fish. Eight experimental groups with replicate tanks were used. Fish were fed (1.5% of biomass) with different diets during the experiment. The uninfected and infected control fish were fed commercial standard non-medicated feed (BioMar A/S) during the entire experiment.
The feed composition for the different treatment groups is shown in Table 1 . The positive control, receiving conventional antibiotic, was fed with commercial standard feed until challenge but received oxolinic acid containing feed from the day of challenge until 14 dpi. Four groups were fed with CAP18-coated feed, and they all received this diet from a week prior to challenge. One group was fed with a dose of 400 lg g À1 feed for only 1 week until challenge, after which the fish were offered non-medicated feed. A second group was fed with the same dose for 3 weeks; that is, feeding was continued after challenge until the end of the experiment. The remaining two groups were fed with the high dose, 800 lg g À1 feed, correspondingly.
Preparation of medicated feed
To avoid leaching of CAP18 from the pellets into the tank water during feeding, the feed was topcoated with CAP18 and fish oil under vacuum allowing the AMP/oil to penetrate pores in the feed pellet. Dry powder of oxolinic acid (1.25 g kg À1 feed) was mixed with fish oil (at room temperature), and feed was top-coated by spraying the mixture on 1.5-mm pelleted feed (BioMar A/S) while stirring. The medicated feed was stored at 4°C.
Challenge of fish receiving CAP18 in feed
After 7 days of feeding with CAP18-coated feed, fish were challenged. Fish from all groups (except uninfected control fish) were challenged by bath exposure to Y. ruckeri O1 biotype 2 (1 9 10 6 CFU mL À1 ) by the procedure described above for efficacy testing. The fish were examined every second hour, and moribund fish were removed, killed and recorded. Water temperature was measured on a daily basis in the course of experiment with a mean of 15°C. In all infection experiments, bacteria were re-isolated on blood agar (head kidney swabs) from moribund fish (2 fish per tank) to confirm that the bacterium causing disease was identical to the challenge strain.
Data analysis
Mortality in the experimental groups is presented as cumulative mortality. Differences among mortality of different groups were tested using Kaplan-Meier plots and one-way ANOVA with Tukey's post hoc test after combining data from the replicates.
Results

Haemolysis assay
The antimicrobial peptide CAP18 showed a minimal haemolytic activity (15.4%) at 10-fold dilution, reducing to zero at further dilutions tested in this study. The other antimicrobial peptides, CAP11 and CAP11-1-18m2, showed a marked haemolytic activity at 10-fold dilution (96.3% and 71.6%, respectively) although the haemolytic activity of these antimicrobial peptides decreased considerably at subsequent dilutions. The solvent DMSO had an adverse effect on blood cells as it elicited a haemolysis of 30% (Fig. 1) . This compound was only used as solvent for CAP11, whereas other AMPs were dissolved in water. Due to the low CAP18 toxicity, this peptide was selected for further analysis.
In vivo experiments
Intraperitoneal
injection. Preliminary experiments. In the first challenge experiment with Y. ruckeri, the highest survival (70%) was recorded Figure 1 Haemolytic activity of different antimicrobial peptides (CAP11, CAP11 mutant and CAP18) on rainbow trout red blood cells (RBCs). in fish injected with 400 lg of CAP18 followed by fish injected with 200 and 100 lg CAP18 (30% survival). The mortality in the 200-lg CAP18 group did not stabilize during the experimental period and must be regarded as a minimum mortality. The exposed but unmedicated control group showed a survival of 20%, and all fish died in the 50-lg CAP18-injected group. The onset of mortality was delayed 1 day in the CAP18-injected group compared to the control group (Fig. 2) . Y. ruckeri was isolated from all killed fish (removed due to disease progression) following challenge.
Main experiment. In the Y. ruckeri infection, the highest survival was recorded in the oxolinic acidinjected group (80%) followed by the CAP18injected (37%) and the control group (13%).
Survival rates of fish groups receiving CAP18 and oxolinic acid were significantly higher (P < 0.05) than the control group (Fig. 3) . No mortalities were observed in na€ ıve uninfected control group during the course of the experiment (Fig. 3) . Y. ruckeri was isolated from all killed fish following challenge.
Oral administration of CAP18
In the feeding experiment, the highest mortalities were recorded in the group fed with CAP18 800 lg g À1 for 1 week (62%), the group receiving CAP18 400 lg g À1 for 3 weeks (52%) and CAP18 400 lg g À1 for 1 week and the infected control (50%). The group fed with CAP18 800 lg g À1 for 3 weeks had lower mortality rates Figure 2 Cumulative mortality (%) of rainbow trout fry intraperitoneally injected with antimicrobial peptide CAP18 or antibiotic oxolinic acid following exposure to Y. ruckeri. Figure 3 Cumulative mortality (%) of rainbow trout fry intraperitoneally injected with antimicrobial peptide CAP18 or antibiotic oxolinic acid and bath-exposed to Y. ruckeri.
(42%). Fish receiving oxolinic acid group showed the lowest mortality (2%) ( Fig. 4; Table 1 ). There was a delay in the onset of disease in the fish fed with oxolinic acid-coated feed (5 dpi) compared to the other groups (Fig. 4) . No disease was observed in na€ ıve uninfected control group during the course of the experiment. Mortality in the oxolinic acid group was significantly lower (P < 0.001) than in the other groups, while there were no significant differences (P > 0.05) between the mortality of the infected control and the other treated groups. The slightly lowered mortality in the CAP18-injected group (42%) compared to the infected control (50%) was not significant (P > 0.05) due to variation of the replicates (mortality rates of 28% and 56%).
Discussion
In the present study, the chemotherapeutic potential in rainbow trout of three cathelicidin antimicrobial peptides, CAP11, CAP11-1-18m2 and CAP18, was evaluated. It was previously shown in vitro that these three AMPs have a bactericidal effect (Ebbensgaard et al. 2015) . However, cytotoxicity studies revealed that CAP11 and CAP11-1-18m2 were able to elicit lysis of rainbow trout RBCs after which these AMPs were excluded from the study. Only CAP18 (18-kDa cationic antimicrobial protein originally isolated and described from rabbit leucocytes) showed high bactericidal activity and low cytotoxicity and was therefore considered a suitable candidate for the in vivo experiments. Earlier studies have also indicated CAP18 to be a promising antimicrobial compound among a range of cationic antimicrobial proteins (Mason et al. 1997; Travis et al. 2000) . We tested both intraperitoneal and oral administration of this antimicrobial peptide and compared it with the action of a well-characterized antibiotic, oxolinic acid. Compared to the non-injected fish, we found that intraperitoneal injection of CAP18 was associated with a significantly lower mortality of rainbow trout exposed to Y. ruckeri. The antimicrobial activity was indicated and corresponded to the action of other AMPs shown to protect fish against other Gram-negative bacteria (Jia et al. 2000; Pan et al. 2007) . When testing oral delivery of CAP18, a high and prolonged dose of 800 lg g À1 applied for 3 weeks led to a slightly higher survival than the other groups orally treated with CAP18, although it was not statistically significant (P > 0.05). In the feeding experiment, fish received AMPs a week prior to infection, but it was obvious that this administration method was not sufficient for prevention of mortality associated with Y. ruckeri exposure. An earlier study on oral administration of AMPs (epinecidin-1) starting 30 days before the experimental bacterial infection with Vibrio vulnificus showed a significantly higher survival in host fishes from 13 dpi (Pan et al. 2012) . Thus, it cannot be excluded that an even longer premedication period based on the administration of CAP18 as feed supplement could lead to improved effect against Y. ruckeri. However, proteolytic Figure 4 Cumulative mortality (%) of rainbow trout fingerlings fed with antimicrobial peptide CAP18 (400 lg g À1 and 800 lg g À1 feed) or antibiotic oxolinic acid or injected with CAP18 (400 lg fish À1 ) following exposure to Y. ruckeri O1 biotype 2 by bath exposure for 6 h. degradation in the fish gastrointestinal tract of the peptides in feed is likely to play a role for the limited effect observed in the present experiment. As these peptides are vulnerable to proteolytic degradation in the gut environment, it may be suggested that the orally administered CAP18 was degraded following ingestion. Therefore, for future studies it may be suggested to improve stability and protease resistance of this peptide by adding compounds such as chitosan or alginate to the feed (Hancock & Sahl 2006; Douglas 2011 ). In addition, although vacuum and oil coating was used for optimizing AMP adhesion to feed pellets, it cannot be excluded that part of the CAP18 leached from the feed following feeding. The suboptimal effect of CAP18 when used in feed together with the high cost of AMP compounds may at present challenge usage of oral CAP18 administration in the aquaculture industry. In conclusion, the results of this study showed that antimicrobial treatment via intraperitoneal injection of CAP18 was associated with an increased survival in rainbow trout infected with Y. ruckeri, whereas oral administration (in-feed administration) was unsuccessful.
